Global Uterine Cancer Drug Market
Tamaño del mercado en miles de millones de dólares
Tasa de crecimiento anual compuesta (CAGR) :
% 
 Período de pronóstico |
2023 –2030 |
 Tamaño del mercado (año base) |
USD 2,412,036.20 Thousand |
 Tamaño del mercado (año de pronóstico) |
USD 4,269,049.34 Thousand |
 Tasa de crecimiento anual compuesta (CAGR) |
% |
| Jugadoras de los principales mercados |
|
>Mercado mundial de medicamentos contra el cáncer de útero, por tipo de cáncer (cáncer de endometrio y sarcoma uterino), tipo de tratamiento (quimioterapia, terapia hormonal, terapia dirigida, inmunoterapia y otros), tipo de medicamento (genérico y de marca), grupo de edad (adultos y geriátricos), vía de administración (oral y parenteral), usuario final (hospitales, centros oncológicos, clínicas especializadas y otros), canal de distribución (licitación directa, ventas minoristas y otros) - Tendencias de la industria y pronóstico hasta 2030.
Análisis y perspectivas del mercado de medicamentos contra el cáncer de útero
El mercado mundial de medicamentos contra el cáncer de útero es un segmento vital dentro de la industria farmacéutica oncológica más amplia, lo que refleja la creciente prevalencia de casos de cáncer de útero en todo el mundo. El cáncer de útero se encuentra entre las neoplasias malignas ginecológicas más comunes, con una tasa de incidencia que ha aumentado de manera constante a lo largo de los años. Varios factores contribuyen a esta tendencia, incluido el envejecimiento de la población, la epidemia de obesidad y la mejora de las capacidades de diagnóstico, lo que conduce a una detección más temprana. Como resultado, el mercado de medicamentos contra el cáncer de útero continúa expandiéndose a medida que las compañías farmacéuticas desarrollan tratamientos innovadores para abordar las necesidades de las pacientes que enfrentan esta desafiante enfermedad.
Los impulsores clave del mercado mundial de medicamentos contra el cáncer de útero incluyen avances en I+D, un énfasis creciente en la medicina de precisión y una comprensión en evolución de los mecanismos moleculares que impulsan el mercado.
Sin embargo, el mercado enfrenta desafíos como el alto costo asociado al tratamiento, la falta de personal calificado y requisitos regulatorios complejos.
Se espera que el mercado mundial de medicamentos contra el cáncer de útero gane crecimiento de mercado en el período de pronóstico de 2023 a 2030. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 8,5% en el período de pronóstico de 2023 a 2030 y se espera que alcance los USD 4.269.049,34 mil para 2030 desde USD 2.412.036,20 mil en 2022.
El informe del mercado mundial de medicamentos contra el cáncer de útero proporciona detalles de la participación de mercado, nuevos desarrollos y análisis de la cartera de productos, el impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsillos de ingresos emergentes, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado, contáctenos para obtener un informe de analista. Nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado. La escalabilidad y la expansión comercial de las unidades minoristas en los países en desarrollo de varias regiones y la asociación con proveedores para la distribución segura de productos de maquinaria y medicamentos son los principales impulsores que impulsaron la demanda del mercado en el período de pronóstico.
|
Métrica del informe |
Detalles |
|
Período de pronóstico |
2023 a 2030 |
|
Año base |
2022 |
|
Años históricos |
2021 (Personalizable para 2015-2020) |
|
Unidades cuantitativas |
Ingresos en miles de USD |
|
Segmentos cubiertos |
Cancer Type (Endometrial Cancer and Uterine Sarcoma), Treatment Type (Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy, and Others), Drug Type (Generic and Branded), Age Group (Adults and Geriatric), Route of Administration (Oral and Parenteral), End User (Hospitals, Cancer Centers, Specialty Clinics, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) |
|
Countries Covered |
U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, rest of Europe, China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Qatar, Kuwait, and rest of Middle East And Africa |
|
Market Players Covered |
Baxter, Accord BioPharma, Inc., Eli Lilly and Company, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Viatris Inc., Sanofi, Teva Pharmaceuticals USA, Inc., Amneal Pharmaceuticals LLC, Merck & Co., Inc., GSK plc., Eisai Co., Ltd., Pfizer Inc., Virtus, and Getwell Oncology among others. |
Global Uterine Cancer Drugs Market Definition
Uterine cancer drugs comprise a class of pharmaceutical drugs and therapies designed specifically to treat and manage uterine cancer, a malignancy originating in the endometrium, the inner lining of the uterus. These drugs play a critical role in the comprehensive treatment and care of individuals diagnosed with uterine cancer. Their primary objectives are to target, suppress, or eliminate cancerous cells within the uterus, thereby slowing or halting the progression of the disease and reducing associated symptoms, such as abnormal uterine bleeding, pelvic pain, and discomfort.
Global Uterine Cancer Drugs Market Dynamics
Drivers
- Rising Incidence of Uterine Cancer Worldwide
In recent years, the world has witnessed a notable surge in the prevalence of uterine cancer, emerging as a significant global health concern. The rising incidence of uterine cancer worldwide is a complex and multifaceted issue, influenced by a combination of genetic, lifestyle, environmental, and healthcare factors.
For instance,
- In March 2023, according to an article published by the American Society of Clinical Oncology (ASCO), uterine cancer is the fourth most common cancer for women in the U.S., worldwide an estimated 417,367 people were diagnosed with uterine cancer in 2020
Thus, the rising incidence of uterine cancer worldwide is driving the market growth.
- Growing Advancements in Targeted Therapy for Uterine Cancer
Los avances en la terapia dirigida para el cáncer de útero han demostrado ser prometedores en cuanto a mejorar los resultados del tratamiento, reducir los efectos secundarios y mejorar la calidad de vida de las pacientes. La terapia dirigida es un tipo de tratamiento del cáncer que se centra en moléculas o vías específicas que intervienen en el crecimiento y la propagación de las células cancerosas, en lugar de afectar de forma generalizada a las células que se dividen rápidamente, como en la quimioterapia tradicional.
Las terapias dirigidas son medicamentos diseñados para atacar cambios específicos en las células cancerosas. Pueden ser útiles en casos de cáncer de útero avanzado o de alto riesgo.
Por ejemplo,
Lenvatinib (Lenvima) es un inhibidor de la cinasa . Impide que los tumores formen nuevos vasos sanguíneos. También actúa sobre las proteínas de las células cancerosas que las ayudan a crecer. Un médico puede utilizar Lenvima en combinación con Keytruda. Se presenta en forma de cápsula oral que se toma todos los días.
Por lo tanto, los crecientes avances en la terapia dirigida para el cáncer de útero están impulsando el crecimiento del mercado.
Oportunidad
- Avances en el análisis de perfiles genómicos y el descubrimiento de biomarcadores
Los avances en la elaboración de perfiles genómicos y el descubrimiento de biomarcadores han tenido un impacto significativo en el tratamiento del cáncer de útero, ofreciendo un enfoque más específico y personalizado para el manejo de la enfermedad. El cáncer de útero abarca una variedad de subtipos, y estos avances han ayudado a identificar variaciones genéticas y características moleculares específicas de cada subtipo, lo que permite estrategias de tratamiento más efectivas.
En conclusión, los avances en la elaboración de perfiles genómicos y el descubrimiento de biomarcadores han transformado el panorama del tratamiento del cáncer de útero. Estos avances han permitido comprender mejor las características genéticas y moleculares de los subtipos de cáncer de útero, ofrecer opciones de tratamiento más específicas y permitir una detección más temprana. Además, son prometedores para mejorar aún más los resultados de las pacientes y ampliar la gama de opciones terapéuticas disponibles para las personas con cáncer de útero a medida que la investigación continúa evolucionando en este campo. Por lo tanto, se espera que los avances en la elaboración de perfiles genómicos y el descubrimiento de biomarcadores actúen como una oportunidad para el crecimiento del mercado.
Desafíos/Restricciones
- El alto costo del tratamiento del cáncer de útero
El cáncer de útero suele requerir un tratamiento multimodal, que puede incluir cirugía, radioterapia, quimioterapia, terapia dirigida y terapia hormonal. Los gastos combinados de estas diversas modalidades de tratamiento, junto con las hospitalizaciones, consultas y visitas de seguimiento asociadas, pueden aumentar significativamente el costo total del tratamiento. Las pacientes con cáncer de útero pueden requerir hospitalización para cirugías, quimioterapia o radioterapia, lo que genera costos sustanciales asociados con las hospitalizaciones, los gastos de quirófano y la atención hospitalaria.
Por lo tanto, el alto costo del tratamiento del cáncer de útero está obstaculizando el crecimiento del mercado.
- Obstáculos regulatorios en el mercado
Los obstáculos regulatorios en el mercado son factores críticos que determinan el desarrollo, la aprobación y la accesibilidad de nuevos tratamientos. Las agencias regulatorias, como la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA), la Agencia Europea de Medicamentos (EMA) y otras, son responsables de garantizar la seguridad, la eficacia y la calidad de los medicamentos. Estas agencias establecen estándares y pautas estrictas que las empresas deben cumplir durante el proceso de desarrollo de medicamentos.
En conclusión, los obstáculos regulatorios en el mercado son multifacéticos y a menudo prolongados.
Por lo tanto, se espera que los obstáculos regulatorios en el mercado actúen como un desafío para el crecimiento del mercado.
Acontecimientos recientes
- En octubre de 2023, Merck and Co., Inc. anunció los resultados del ensayo de fase 3 KEYNOTE-A39 (también conocido como EV-302), que se llevó a cabo en colaboración con Seagen y Astellas, en el que se comparó KEYTRUDA, la terapia anti-PD-1 de Merck, más Padcev (enfortumab vedotin-ejfv), un conjugado anticuerpo-fármaco, en comparación con la quimioterapia (gemcitabina más cisplatino o carboplatino) en pacientes con carcinoma urotelial avanzado o metastásico no tratado anteriormente. Esto ayudará a la empresa a ampliar la aplicación de su marca KEYTRUDA.
- En diciembre de 2022, Sanofi e Innate Pharma SA anunciaron una ampliación de su colaboración, con la concesión por parte de Sanofi de la licencia de un programa de captación de células Natural Killer (NK) dirigido a B7H3 de la plataforma ANKETTM (Antibody-based NK Cell Engager Therapeutics) de Innate. Sanofi también tendrá la opción de añadir hasta dos dianas ANKETTM adicionales. Tras la selección de candidatos, Sanofi será responsable de todo el desarrollo, la fabricación y la comercialización. Esta colaboración ayudará a ampliar la cartera de oncología de Sanofi en el mercado global.
Alcance del mercado mundial de medicamentos contra el cáncer de útero
El mercado mundial de medicamentos contra el cáncer de útero se clasifica en cinco segmentos notables según el tipo de cáncer, el tipo de tratamiento, el tipo de medicamento, el grupo de edad, la vía de administración, el usuario final y el canal de distribución. El crecimiento entre segmentos lo ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus áreas de aplicación principales y la diferencia en sus mercados objetivo.
Tipo de cáncer
- Cáncer de endometrio
- Sarcoma uterino
Según el tipo de cáncer, el mercado está segmentado en cáncer de endometrio y sarcoma uterino.
Tipo de tratamiento
- Quimioterapia
- Inmunoterapia
- Terapia hormonal
- Terapia dirigida
- Otros
Según el tipo de tratamiento, el mercado está segmentado en quimioterapia, inmunoterapia, terapia hormonal, terapia dirigida y otros.
Tipo de droga
- Genéricos
- De marca
Según el tipo de medicamento, el mercado se segmenta en genéricos y de marca.
Grupo de edad
- Geriátrico
- Adultos
En función del grupo de edad, el mercado se segmenta en geriátrico y adultos.
Vía de administración
- Parenteral
- Oral
Según la vía de administración, el mercado está segmentado en parenteral y oral.
Usuario final
- Hospitales
- Centros de cáncer
- Clínicas de especialidades
- Otros
On the basis of end-user, the market is segmented into hospitals, cancer centers, specialty clinics, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channel, the global uterine cancer drug market is segmented into direct tender, retail sales, and others.
Regional Analysis/Insights: Global Uterine Cancer Drugs Market
The global uterine cancer drugs market is categorized into seven notable segments such as cancer type, treatment type, drug type, age group, route of administration, end-user, and distribution channel.
The countries covered in this market report U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, rest of Europe, China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Qatar, Kuwait, and rest of Middle East And Africa.
The U.S. is expected to dominate the North America region due to the rise in technological advancement in uterine cancer drugs products market. Germany is expected to dominate the Europe region due to the strong presence of key players. China is expected to dominate the Asia-Pacific region due to the mass production of uterine cancer drugs based products and increasing demand from emerging markets and expansion.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Share Analysis: Global Uterine Cancer Drugs Market
Global uterine cancer drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, product type lifeline curve. The above data points provided are only related to the company’s focus on the Global Uterine Cancer Drugs market.
Algunos de los principales actores que operan en el mercado global de medicamentos contra el cáncer de útero son Baxter, Accord BioPharma, Inc., Eli Lilly and Company, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Viatris Inc., Sanofi, Teva Pharmaceuticals USA, Inc., Amneal Pharmaceuticals LLC, Merck & Co., Inc., GSK plc., Eisai Co., Ltd., Pfizer Inc., Virtus y Getwell Oncology, entre otros.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL UTERINE CANCER DRUGS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 CANCER TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER'S 5 FORCES
4.3 EPIDEMIOLOGY
5 GLOBAL UTERINE CANCER DRUGS MARKET, REGULATORY FRAMEWORK
5.1 OVERVIEW
5.2 REGULATION IN THE U.S.
5.3 REGULATION IN CANADA
5.4 REGULATION IN EUROPE
5.5 REGULATION IN CHINA
5.6 REGULATION IN JAPAN
5.7 REGULATION IN AUSTRALIA
5.8 REGULATION IN INDIA
5.9 REGULATION IN BRAZIL
5.1 REGULATION IN SOUTH AFRICA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING INCIDENCE OF UTERINE CANCER WORLDWIDE
6.1.2 GROWING ADVANCEMENTS IN TARGETED THERAPY FOR UTERINE CANCER
6.1.3 RISING AWARENESS OF UTERINE CANCER
6.1.4 RISING COLLABORATIONS AND PARTNERSHIPS AMONG LEADING PLAYERS
6.2 RESTRAINTS
6.2.1 HIGH COST OF UTERINE CANCER TREATMENT
6.2.2 SIDE EFFECTS AND TOXICITY ASSOCIATED WITH CANCER DRUGS
6.3 OPPORTUNITIES
6.3.1 ADVANCEMENTS IN GENOMIC PROFILING AND BIOMARKER DISCOVERY
6.3.2 GROWING R&D ACTIVITIES FOR UTERINE CANCER TREATMENT
6.4 CHALLENGES
6.4.1 REGULATORY HURDLES IN THE UTERINE CANCER DRUGS MARKET
6.4.2 DRUG RESISTANCE IN THE TREATMENT OF UTERINE CANCER
7 GLOBAL UTERINE CANCER DRUGS MARKET, BY CANCER TYPE
7.1 OVERVIEW
7.2 ENDOMETRIAL CANCER
7.2.1 UTERINE CARCINOSARCOMA
7.2.2 SEROUS ADENOSARCOMA
7.2.3 ADENOSQUAMOUS CARCINOMA
7.2.4 OTHER
7.3 UTERINE SARCOMA
7.3.1 UTERINE LEIOMYOSARCOMA
7.3.2 ENDOMETRIAL STROMAL SARCOMAS
7.3.3 UNDIFFERENTIATED SARCOMA
8 GLOBAL UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE
8.1 OVERVIEW
8.2 CHEMOTHERAPY
8.2.1 PACLITAXEL
8.2.2 CARBOPLATIN
8.2.3 CISPLATIN
8.2.4 DOXORUBICIN
8.2.5 DOCETAXEL
8.2.6 OTHERS
8.3 IMMUNOTHERAPY
8.4 HORMONE THERAPY
8.4.1 PROGESTINS
8.4.1.1 MEDROXYPROGESTERONE ACETATE
8.4.1.2 OTHERS
8.4.2 AROMATASE INHIBITORS
8.4.2.1 LETRAZOLE
8.4.2.2 ANASTRAZOLE
8.4.2.3 EXEMESTANE
8.4.3 LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS
8.4.3.1 GOSERELIN
8.4.3.2 LEUPROLIDE
8.4.4 OTHERS
8.5 TARGETED THERAPY
8.5.1 LENVATINAB
8.5.2 BEVACIZUMAB
8.5.3 MTOR INHIBITORS
8.5.3.1 EVEROLIMUS
8.5.3.2 TEMSIROLIMUS
8.6 OTHERS
9 GLOBAL UTERINE CANCER DRUGS MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 GENERICS
9.3 BRANDED
9.3.1 KEYTRUDA
9.3.2 LENVIMA
9.3.3 PROVERA
9.3.4 TEMODAR
9.3.5 JEMPERLI
9.3.6 OTHERS
10 GLOBAL UTERINE CANCER DRUGS MARKET, BY AGE GROUP
10.1 OVERVIEW
10.2 GERIATRIC
10.3 ADULTS
11 GLOBAL UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 PARENTERAL
11.3 ORAL
12 GLOBAL UTERINE CANCER DRUGS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.2.1 PRIVATE
12.2.2 PUBLIC
12.3 CANCER CENTERS
12.4 SPECIALTY CLINICS
12.5 OTHERS
13 GLOBAL UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.3.1 HOSPITAL PHARMACY
13.3.2 RETAIL PHARMACY
13.3.3 ONLINE PHARMACY
13.4 OTHERS
14 GLOBAL UTERINE CANCER DRUGS MARKET, BY REGION
14.1 OVERVIEW
14.2 NORTH AMERICA
14.2.1 U.S.
14.2.2 CANADA
14.2.3 MEXICO
14.3 EUROPE
14.3.1 GERMANY
14.3.2 U.K.
14.3.3 FRANCE
14.3.4 RUSSIA
14.3.5 ITALY
14.3.6 SPAIN
14.3.7 TURKEY
14.3.8 BELGIUM
14.3.9 NETHERLANDS
14.3.10 SWITZERLAND
14.3.11 REST OF EUROPE
14.4 ASIA-PACIFIC
14.4.1 CHINA
14.4.2 JAPAN
14.4.3 INDIA
14.4.4 AUSTRALIA
14.4.5 SOUTH KOREA
14.4.6 NEW ZEALAND
14.4.7 SINGAPORE
14.4.8 THAILAND
14.4.9 MALAYSIA
14.4.10 INDONESIA
14.4.11 PHILIPPINES
14.4.12 REST OF ASIA-PACIFIC
14.5 SOUTH AMERICA
14.5.1 BRAZIL
14.5.2 ARGENTINA
14.5.3 REST OF SOUTH AMERICA
14.6 MIDDLE EAST AND AFRICA
14.6.1 SAUDI ARABIA
14.6.2 U.A.E.
14.6.3 SOUTH AFRICA
14.6.4 EGYPT
14.6.5 KUWAIT
14.6.6 REST OF MIDDLE EAST AFRICA
15 GLOBAL UTERINE CANCER DRUGS MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16 SWOT ANALYSIS
17 COMPANY PROFILES
17.1 MERCK & CO., INC.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 EISAI CO., LTD.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.2.6 RECENT DEVELOPMENT
17.3 SANOFI
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 PFIZER INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 TEVA PHARMACEUTICALS USA, INC.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENT
17.6 ACCORD HEALTHCARE US.
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENT
17.7 AMNEAL PHARMACEUTICALS LLC
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 BAXTER
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 COMPANY SHARE ANALYSIS
17.8.4 PRODUCT PORTFOLIO
17.8.5 RECENT DEVELOPMENT
17.9 ELI LILLY AND COMPANY
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENT
17.1 GETWELL ONCOLOGY
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 GSK PLC.
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.12 HIKMA PHARMACEUTICALS PLC
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENT
17.13 SUN PHARMACEUTICAL INDUSTRIES LTD.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 VIATRIS INC.
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENT
17.15 VIRTUS
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
Lista de Tablas
TABLE 1 GLOBAL UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2022-2030 (USD THOUSAND)
TABLE 2 GLOBAL ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 3 GLOBAL ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 4 GLOBAL UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 5 GLOBAL UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 6 GLOBAL UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 7 GLOBAL CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 8 GLOBAL CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 9 GLOBAL IMMUNOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 10 GLOBAL HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 11 GLOBAL HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 12 GLOBAL PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 13 GLOBAL AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 14 GLOBAL LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 15 GLOBAL TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 16 GLOBAL TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 17 GLOBAL MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 18 GLOBAL OTHERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 19 GLOBAL UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 20 GLOBAL GENERICS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 21 GLOBAL BRANDED IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 22 GLOBAL BRANDED IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 23 GLOBAL UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2022-2030 (USD THOUSAND)
TABLE 24 GLOBAL GERIATRIC IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 25 GLOBAL ADULTS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 26 GLOBAL UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 27 GLOBAL PARENTERAL IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 28 GLOBAL ORAL IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 29 GLOBAL UTERINE CANCER DRUGS MARKET, BY END USER, 2022-2030 (USD THOUSAND)
TABLE 30 GLOBAL HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 31 GLOBAL HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 32 GLOBAL CANCER CENTERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 33 GLOBAL SPECIALTY CLINICS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 34 GLOBAL OTHERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 35 GLOBAL UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD THOUSAND)
TABLE 36 GLOBAL DIRECT TENDER IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 37 GLOBAL RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 38 GLOBAL RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 39 GLOBAL OTHERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 40 GLOBAL UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 41 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 42 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 43 NORTH AMERICA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 44 NORTH AMERICA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 45 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 46 NORTH AMERICA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 47 NORTH AMERICA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 48 NORTH AMERICA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 49 NORTH AMERICA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 50 NORTH AMERICA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 51 NORTH AMERICA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 52 NORTH AMERICA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 53 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 54 NORTH AMERICA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 55 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 56 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 57 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 58 NORTH AMERICA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 59 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 60 NORTH AMERICA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 61 U.S. UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 62 U.S. ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 63 U.S. UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 64 U.S. UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 65 U.S. CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 66 U.S. HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 67 U.S. PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 68 U.S. AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 69 U.S. LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 70 U.S. TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 71 U.S. MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 72 U.S. UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 73 U.S. BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 74 U.S. UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 75 U.S. UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 76 U.S. UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 77 U.S. HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 78 U.S. UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 79 U.S. RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 80 CANADA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 81 CANADA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 82 CANADA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 83 CANADA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 84 CANADA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 85 CANADA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 86 CANADA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 87 CANADA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 88 CANADA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 89 CANADA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 90 CANADA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 91 CANADA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 92 CANADA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 93 CANADA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 94 CANADA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 95 CANADA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 96 CANADA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 97 CANADA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 98 CANADA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 99 MEXICO UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 100 MEXICO ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 101 MEXICO UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 102 MEXICO UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 103 MEXICO CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 104 MEXICO HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 105 MEXICO PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 106 MEXICO AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 107 MEXICO LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 108 MEXICO TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 109 MEXICO MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 110 MEXICO UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 111 MEXICO BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 112 MEXICO UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 113 MEXICO UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 114 MEXICO UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 115 MEXICO HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 116 MEXICO UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 117 MEXICO RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 118 EUROPE UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 119 EUROPE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 120 EUROPE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 121 EUROPE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 122 EUROPE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 123 EUROPE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 124 EUROPE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 125 EUROPE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 126 EUROPE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 127 EUROPE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 128 EUROPE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 129 EUROPE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 130 EUROPE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 131 EUROPE BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 132 EUROPE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 133 EUROPE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 134 EUROPE UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 135 EUROPE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 136 EUROPE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 137 EUROPE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 138 GERMANY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 139 GERMANY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 140 GERMANY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 141 GERMANY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 142 GERMANY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 143 GERMANY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 144 GERMANY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 145 GERMANY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 146 GERMANY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 147 GERMANY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 148 GERMANY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 149 GERMANY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 150 GERMANY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 151 GERMANY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 152 GERMANY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 153 GERMANY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 154 GERMANY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 155 GERMANY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 156 GERMANY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 157 U.K. UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 158 U.K. ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 159 U.K. UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 160 U.K. UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 161 U.K. CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 162 U.K. HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 163 U.K. PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 164 U.K. AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 165 U.K. LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 166 U.K. TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 167 U.K. MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 168 U.K. UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 169 U.K. BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 170 U.K. UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 171 U.K. UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 172 U.K. UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 173 U.K. HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 174 U.K. UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 175 U.K. RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 176 FRANCE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 177 FRANCE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 178 FRANCE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 179 FRANCE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 180 FRANCE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 181 FRANCE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 182 FRANCE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 183 FRANCE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 184 FRANCE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 185 FRANCE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 186 FRANCE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 187 FRANCE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 188 FRANCE BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 189 FRANCE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 190 FRANCE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 191 FRANCE UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 192 FRANCE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 193 FRANCE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 194 FRANCE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 195 RUSSIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 196 RUSSIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 197 RUSSIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 198 RUSSIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 199 RUSSIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 200 RUSSIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 201 RUSSIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 202 RUSSIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 203 RUSSIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 204 RUSSIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 205 RUSSIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 206 RUSSIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 207 RUSSIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 208 RUSSIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 209 RUSSIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 210 RUSSIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 211 RUSSIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 212 RUSSIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 213 RUSSIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 214 ITALY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 215 ITALY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 216 ITALY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 217 ITALY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 218 ITALY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 219 ITALY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 220 ITALY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 221 ITALY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 222 ITALY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 223 ITALY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 224 ITALY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 225 ITALY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 226 ITALY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 227 ITALY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 228 ITALY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 229 ITALY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 230 ITALY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 231 ITALY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 232 ITALY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 233 SPAIN UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 234 SPAIN ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 235 SPAIN UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 236 SPAIN UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 237 SPAIN CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 238 SPAIN HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 239 SPAIN PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 240 SPAIN AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 241 SPAIN LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 242 SPAIN TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 243 SPAIN MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 244 SPAIN UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 245 SPAIN BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 246 SPAIN UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 247 SPAIN UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 248 SPAIN UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 249 SPAIN HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 250 SPAIN UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 251 SPAIN RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 252 TURKEY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 253 TURKEY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 254 TURKEY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 255 TURKEY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 256 TURKEY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 257 TURKEY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 258 TURKEY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 259 TURKEY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 260 TURKEY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 261 TURKEY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 262 TURKEY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 263 TURKEY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 264 TURKEY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 265 TURKEY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 266 TURKEY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 267 TURKEY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 268 TURKEY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 269 TURKEY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 270 TURKEY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 271 BELGIUM UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 272 BELGIUM ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 273 BELGIUM UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 274 BELGIUM UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 275 BELGIUM CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 276 BELGIUM HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 277 BELGIUM PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 278 BELGIUM AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 279 BELGIUM LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 280 BELGIUM TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 281 BELGIUM MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 282 BELGIUM UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 283 BELGIUM BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 284 BELGIUM UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 285 BELGIUM UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 286 BELGIUM UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 287 BELGIUM HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 288 BELGIUM UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 289 BELGIUM RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 290 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 291 NETHERLANDS ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 292 NETHERLANDS UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 293 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 294 NETHERLANDS CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 295 NETHERLANDS HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 296 NETHERLANDS PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 297 NETHERLANDS AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 298 NETHERLANDS LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 299 NETHERLANDS TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 300 NETHERLANDS MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 301 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 302 NETHERLANDS BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 303 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 304 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 305 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 306 NETHERLANDS HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 307 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 308 NETHERLANDS RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 309 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 310 SWITZERLAND ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 311 SWITZERLAND UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 312 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 313 SWITZERLAND CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 314 SWITZERLAND HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 315 SWITZERLAND PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 316 SWITZERLAND AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 317 SWITZERLAND LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 318 SWITZERLAND TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 319 SWITZERLAND MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 320 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 321 SWITZERLAND BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 322 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 323 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 324 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 325 SWITZERLAND HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 326 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 327 SWITZERLAND RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 328 REST OF EUROPE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 329 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 330 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 331 ASIA-PACIFIC ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 332 ASIA-PACIFIC UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 333 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 334 ASIA-PACIFIC CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 335 ASIA-PACIFIC HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 336 ASIA-PACIFIC PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 337 ASIA-PACIFIC AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 338 ASIA-PACIFIC LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 339 ASIA-PACIFIC TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 340 ASIA-PACIFIC MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 341 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 342 ASIA-PACIFIC BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 343 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 344 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 345 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 346 ASIA-PACIFIC HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 347 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 348 ASIA-PACIFIC RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 349 CHINA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 350 CHINA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 351 CHINA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 352 CHINA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 353 CHINA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 354 CHINA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 355 CHINA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 356 CHINA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 357 CHINA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 358 CHINA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 359 CHINA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 360 CHINA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 361 CHINA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 362 CHINA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 363 CHINA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 364 CHINA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 365 CHINA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 366 CHINA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 367 CHINA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 368 JAPAN UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 369 JAPAN ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 370 JAPAN UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 371 JAPAN UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 372 JAPAN CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 373 JAPAN HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 374 JAPAN PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 375 JAPAN AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 376 JAPAN LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 377 JAPAN TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 378 JAPAN MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 379 JAPAN UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 380 JAPAN BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 381 JAPAN UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 382 JAPAN UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 383 JAPAN UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 384 JAPAN HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 385 JAPAN UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 386 JAPAN RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 387 INDIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 388 INDIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 389 INDIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 390 INDIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 391 INDIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 392 INDIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 393 INDIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 394 INDIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 395 INDIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 396 INDIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 397 INDIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 398 INDIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 399 INDIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 400 INDIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 401 INDIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 402 INDIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 403 INDIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 404 INDIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 405 INDIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 406 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 407 AUSTRALIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 408 AUSTRALIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 409 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 410 AUSTRALIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 411 AUSTRALIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 412 AUSTRALIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 413 AUSTRALIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 414 AUSTRALIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 415 AUSTRALIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 416 AUSTRALIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 417 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 418 AUSTRALIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 419 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 420 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 421 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 422 AUSTRALIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 423 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 424 AUSTRALIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 425 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 426 SOUTH KOREA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 427 SOUTH KOREA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 428 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 429 SOUTH KOREA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 430 SOUTH KOREA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 431 SOUTH KOREA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 432 SOUTH KOREA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 433 SOUTH KOREA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 434 SOUTH KOREA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 435 SOUTH KOREA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 436 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 437 SOUTH KOREA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 438 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 439 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 440 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 441 SOUTH KOREA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 442 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 443 SOUTH KOREA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 444 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 445 NEW ZEALAND ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 446 NEW ZEALAND UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 447 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 448 NEW ZEALAND CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 449 NEW ZEALAND HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 450 NEW ZEALAND PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 451 NEW ZEALAND AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 452 NEW ZEALAND LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 453 NEW ZEALAND TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 454 NEW ZEALAND MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 455 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 456 NEW ZEALAND BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 457 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 458 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 459 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 460 NEW ZEALAND HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 461 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 462 NEW ZEALAND RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 463 SINGAPORE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 464 SINGAPORE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 465 SINGAPORE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 466 SINGAPORE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 467 SINGAPORE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 468 SINGAPORE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 469 SINGAPORE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 470 SINGAPORE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 471 SINGAPORE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 472 SINGAPORE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 473 SINGAPORE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 474 SINGAPORE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 475 SINGAPORE BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 476 SINGAPORE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 477 SINGAPORE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 478 SINGAPORE UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 479 SINGAPORE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 480 SINGAPORE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 481 SINGAPORE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 482 THAILAND UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 483 THAILAND ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 484 THAILAND UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 485 THAILAND UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 486 THAILAND CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 487 THAILAND HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 488 THAILAND PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 489 THAILAND AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 490 THAILAND LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 491 THAILAND TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 492 THAILAND MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 493 THAILAND UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 494 THAILAND BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 495 THAILAND UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 496 THAILAND UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 497 THAILAND UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 498 THAILAND HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 499 THAILAND UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 500 THAILAND RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 501 MALAYSIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 502 MALAYSIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 503 MALAYSIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 504 MALAYSIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 505 MALAYSIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 506 MALAYSIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 507 MALAYSIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 508 MALAYSIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 509 MALAYSIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 510 MALAYSIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 511 MALAYSIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 512 MALAYSIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 513 MALAYSIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 514 MALAYSIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 515 MALAYSIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 516 MALAYSIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 517 MALAYSIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 518 MALAYSIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 519 MALAYSIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 520 INDONESIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 521 INDONESIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 522 INDONESIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 523 INDONESIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 524 INDONESIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 525 INDONESIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 526 INDONESIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 527 INDONESIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 528 INDONESIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 529 INDONESIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 530 INDONESIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 531 INDONESIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 532 INDONESIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 533 INDONESIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 534 INDONESIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 535 INDONESIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 536 INDONESIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 537 INDONESIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 538 INDONESIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 539 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 540 PHILIPPINES ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 541 PHILIPPINES UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 542 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 543 PHILIPPINES CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 544 PHILIPPINES HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 545 PHILIPPINES PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 546 PHILIPPINES AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 547 PHILIPPINES LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 548 PHILIPPINES TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 549 PHILIPPINES MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 550 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 551 PHILIPPINES BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 552 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 553 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 554 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 555 PHILIPPINES HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 556 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 557 PHILIPPINES RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 558 REST OF ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 559 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 560 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 561 SOUTH AMERICA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 562 SOUTH AMERICA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 563 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 564 SOUTH AMERICA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 565 SOUTH AMERICA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 566 SOUTH AMERICA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 567 SOUTH AMERICA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 568 SOUTH AMERICA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 569 SOUTH AMERICA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 570 SOUTH AMERICA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 571 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 572 SOUTH AMERICA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 573 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 574 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 575 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 576 SOUTH AMERICA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 577 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 578 SOUTH AMERICA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 579 BRAZIL UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 580 BRAZIL ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 581 BRAZIL UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 582 BRAZIL UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 583 BRAZIL CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 584 BRAZIL HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 585 BRAZIL PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 586 BRAZIL AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 587 BRAZIL LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 588 BRAZIL TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 589 BRAZIL MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 590 BRAZIL UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 591 BRAZIL BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 592 BRAZIL UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 593 BRAZIL UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 594 BRAZIL UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 595 BRAZIL HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 596 BRAZIL UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 597 BRAZIL RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 598 ARGENTINA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 599 ARGENTINA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 600 ARGENTINA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 601 ARGENTINA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 602 ARGENTINA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 603 ARGENTINA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 604 ARGENTINA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 605 ARGENTINA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 606 ARGENTINA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 607 ARGENTINA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 608 ARGENTINA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 609 ARGENTINA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 610 ARGENTINA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 611 ARGENTINA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 612 ARGENTINA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 613 ARGENTINA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 614 ARGENTINA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 615 ARGENTINA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 616 ARGENTINA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 617 REST OF SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 618 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 619 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 620 MIDDLE EAST AND AFRICA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 621 MIDDLE EAST AND AFRICA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 622 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 623 MIDDLE EAST AND AFRICA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 624 MIDDLE EAST AND AFRICA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 625 MIDDLE EAST AND AFRICA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 626 MIDDLE EAST AND AFRICA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 627 MIDDLE EAST AND AFRICA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 628 MIDDLE EAST AND AFRICA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 629 MIDDLE EAST AND AFRICA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 630 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 631 MIDDLE EAST AND AFRICA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 632 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 633 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 634 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 635 MIDDLE EAST AND AFRICA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 636 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 637 MIDDLE EAST AND AFRICA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 638 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 639 SAUDI ARABIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 640 SAUDI ARABIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 641 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 642 SAUDI ARABIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 643 SAUDI ARABIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 644 SAUDI ARABIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 645 SAUDI ARABIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 646 SAUDI ARABIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 647 SAUDI ARABIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 648 SAUDI ARABIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 649 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 650 SAUDI ARABIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 651 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 652 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 653 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 654 SAUDI ARABIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 655 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 656 SAUDI ARABIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 657 U.A.E. UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 658 U.A.E. ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 659 U.A.E. UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 660 U.A.E. UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 661 U.A.E. CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 662 U.A.E. HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 663 U.A.E. PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 664 U.A.E. AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 665 U.A.E. LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 666 U.A.E. TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 667 U.A.E. MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 668 U.A.E. UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 669 U.A.E. BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 670 U.A.E. UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 671 U.A.E. UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 672 U.A.E. UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 673 U.A.E. HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 674 U.A.E. UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 675 U.A.E. RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 676 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 677 SOUTH AFRICA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 678 SOUTH AFRICA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 679 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 680 SOUTH AFRICA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 681 SOUTH AFRICA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 682 SOUTH AFRICA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 683 SOUTH AFRICA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 684 SOUTH AFRICA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 685 SOUTH AFRICA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 686 SOUTH AFRICA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 687 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 688 SOUTH AFRICA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 689 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 690 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 691 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 692 SOUTH AFRICA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 693 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 694 SOUTH AFRICA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 695 EGYPT UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 696 EGYPT ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 697 EGYPT UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 698 EGYPT UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 699 EGYPT CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 700 EGYPT HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 701 EGYPT PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 702 EGYPT AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 703 EGYPT LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 704 EGYPT TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 705 EGYPT MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 706 EGYPT UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 707 EGYPT BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 708 GYPT UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 709 EGYPT UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 710 EGYPT UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 711 EGYPT HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 712 EGYPT UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 713 EGYPT RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 714 KUWAIT UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 715 KUWAIT ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 716 KUWAIT UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 717 KUWAIT UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 718 KUWAIT CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 719 KUWAIT HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 720 KUWAIT PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 721 KUWAIT AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 722 KUWAIT LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 723 KUWAIT TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 724 KUWAIT MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 725 KUWAIT UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 726 KUWAIT BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 727 KUWAIT UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 728 KUWAIT UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 729 KUWAIT UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 730 KUWAIT HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 731 KUWAIT UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 732 KUWAIT RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 733 REST OF MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
Lista de figuras
FIGURE 1 GLOBAL UTERINE CANCER DRUGS MARKET: SEGMENTATION
FIGURE 2 GLOBAL UTERINE CANCER DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL UTERINE CANCER DRUGS MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL UTERINE CANCER DRUGS MARKET : GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL UTERINE CANCER DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL UTERINE CANCER DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL UTERINE CANCER DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL UTERINE CANCER DRUGS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 GLOBAL UTERINE CANCER DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL UTERINE CANCER DRUGS MARKET: SEGMENTATION
FIGURE 11 RISING INCIDENCE OF UTERINE CANCER IS EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 12 ENDOMETRIAL CANCER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 AND 2030
FIGURE 13 NORTH AMEIRCA IS EXPECTED TO DOMINATE THE GLOBAL UTERINE CANCER DRUGS MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 14 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR UTERINE CANCER DRUG MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL UTERINE CANCER DRUGS MARKET
FIGURE 16 GLOBAL UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2022
FIGURE 17 GLOBAL UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2023-2030 (USD THOUSAND)
FIGURE 18 GLOBAL UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 19 GLOBAL UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 20 GLOBAL UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2022
FIGURE 21 GLOBAL UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND)
FIGURE 22 GLOBAL UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, CAGR (2023-2030)
FIGURE 23 GLOBAL UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 24 GLOBAL UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2022
FIGURE 25 GLOBAL UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND)
FIGURE 26 GLOBAL UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 27 GLOBAL UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 28 GLOBAL UTERINE CANCER DRUGS MARKET: BY TYPE, 2022
FIGURE 29 GLOBAL UTERINE CANCER DRUGS MARKET: BY AGE GROUP, 2023-2030 (USD THOUSAND)
FIGURE 30 GLOBAL UTERINE CANCER DRUGS MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 31 GLOBAL UTERINE CANCER DRUGS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 32 GLOBAL UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 33 GLOBAL UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)
FIGURE 34 GLOBAL UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 35 GLOBAL UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 36 GLOBAL UTERINE CANCER DRUGS MARKET: BY END USER, 2022
FIGURE 37 GLOBAL UTERINE CANCER DRUGS MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 38 GLOBAL UTERINE CANCER DRUGS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 39 GLOBAL UTERINE CANCER DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 GLOBAL UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 41 GLOBAL UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 42 GLOBAL UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 43 GLOBAL UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 GLOBAL UTERINE CANCER DRUGS MARKET: SNAPSHOT (2022)
FIGURE 45 GLOBAL UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)
FIGURE 46 NORTH AMERICA UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)
FIGURE 47 EUROPE UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)
FIGURE 48 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
